BRU · ARGX.BR
argenx SE
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
Loading market information…
NASDAQ · QURE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
uniQure N.V.’s quoted price sits in the lower half of its reported 52-week range, 63.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
uniQure N.V.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.92. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow uniQure N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 9, 2025 |
| -$0.82+23.36% vs estimate |
| $1.57M-73.43% vs estimate |
| Q4 2024 | Feb 27, 2025 | -$1.50-150.0% vs estimate | $5.22M-71.69% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$0.91+18.75% vs estimate | $2.29M-87.52% vs estimate |
|---|
THE ANALYST VIEW
38 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $48.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
$16.78-$0.42 (-2.44%)
Ultragenyx Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$7.41+$0.17 (+2.35%)
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
$1.76-$0.08 (-4.35%)
Voyager Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.88% below the high.
